Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Cancer Therapies02:49

Cancer Therapies

10.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exosomal CircGANAB promotes cancer progression and immunotherapy resistance by degrading interacting RNAs and limiting T cell infiltration in pancreatic ductal adenocarcinoma.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
Same author

CircZBTB44-Encoded Peptide ZBTB44-342aa Alleviates Aortic Valve Calcification Via cGAS-STING Inhibition.

Circulation research·2026
Same author

Corrigendum to "B cell CLL/lymphoma 6 member B inhibits hepatocellular carcinoma metastases in vitro and in mice" [Cancer Lett. 355 (2014) 192-200].

Cancer letters·2025
Same author

Trimethylamine N-oxide aggravates human aortic valve interstitial cell inflammation by regulating the macrophages polarization through a N6-methyladenosine-mediated pathway.

Atherosclerosis·2025
Same author

Interleukin-37 attenuates aortic valve lesions by inhibiting N6-methyladenosine-mediated interleukin-1 receptor-associated kinase M degradation.

Cardiovascular research·2025
Same author

Dynamic roles of tumor-infiltrating B lymphocytes in cancer immunotherapy.

Cancer immunology, immunotherapy : CII·2025

Related Experiment Video

Updated: Apr 15, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

8.9K

Targeting EZH2 for cancer therapy: progress and perspective.

Chi Han Li, Yangchao Chen1

  • 1School of Biomedical Sciences, Faculty of Medicine, the Chinese University of Hong Kong, Shatin, NT, Hong Kong. frankch@cuhk.edu.hk.

Current Protein & Peptide Science
|April 10, 2015
PubMed
Summary

Targeting Enhancer of Zeste Homolog 2 (EZH2) shows therapeutic potential in cancer. This review explores current strategies and future directions for inhibiting EZH2 to combat oncogenesis.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

988

Related Experiment Videos

Last Updated: Apr 15, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

8.9K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

988

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Enhancer of Zeste Homolog 2 (EZH2) is a key component of the Polycomb Repressive Complex 2 (PRC2).
  • EZH2 catalyzes histone H3 lysine 27 di/trimethylation, regulating gene expression.
  • Dysregulation of EZH2 is implicated in various cancers, highlighting its oncogenic role.

Purpose of the Study:

  • To review current strategies for targeting EZH2 in cancer treatment.
  • To evaluate existing compounds and agents that inhibit EZH2 function.
  • To provide insights into future research directions for EZH2-targeted cancer therapies.

Main Methods:

  • Comprehensive literature review of EZH2 structure, function, and PRC2 assembly.
  • Analysis of molecular mechanisms for EZH2 recruitment to genomic regions.
  • Discussion of EZH2 post-translational modifications.
  • Evaluation of current EZH2 inhibitors and therapeutic strategies.

Main Results:

  • EZH2 plays critical roles in development and its aberrant activity drives oncogenesis.
  • Targeting EZH2 presents significant therapeutic potential in diverse cancer types.
  • Current strategies focus on disrupting EZH2 enzymatic activity and protein interactions.

Conclusions:

  • Understanding EZH2's structure, function, and regulation is crucial for developing effective cancer therapies.
  • Novel strategies are needed to abolish EZH2-driven oncogenic effects.
  • Further research into EZH2 pathways and inhibitors will advance cancer treatment options.